Qiaoli Hua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiaoli Hua has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Banghan Ding
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication - Bing Feng
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510120, China
1 shared publication - Bo Yu
General Surgery, The Second People’s Hospital of Lanzhou, Lanzhou, China
1 shared publication - Chenghui Li
Department of Internal Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China
1 shared publication - Danwen Zheng
Department of Emergency, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China
1 shared publication - Danwen Zheng
Emergency Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China
1 shared publication
Latest Publications
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46375
Effect of Fuzheng series of formulas on the psychological state, dyspnea, and quality of life in convalescent COVID-19 patients: A retrospective observational study
Post-infectious symptoms of COVID-19—such as persistent dyspnea, psychological disturbances, and reduced quality of life—continue to pose significant health challenges for convalescent patients. Traditional Chinese Medicine (TCM) has been widely used as a complementary therapeutic approach to alleviate post-COVID sequelae. This retrospective study evaluated the clinical effects of 2 TCM prescriptions, Fuzheng Yifei Formula (FZYF) and Fuzheng Anshen Formula (FZAS), on the psychological state, dyspnea, and quality of life among patients recovering from COVID-19. Medical records of 114 COVID-19 convalescent patients treated at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine were retrospectively reviewed. Based on the treatment regimen, patients were categorized into 2 groups: FZYF (n = 77) and FZAS (n = 37). Clinical data were collected at baseline, 7 days, 14 days, and during follow-up. Changes in psychological status, dyspnea severity, and quality-of-life scores were analyzed using validated assessment tools, including the General Health Questionnaire (GHQ-12), the Modified Borg Scale, and the 36-Item Short Form Survey (SF-36) Health Survey. Both FZYF and FZAS were associated with significant improvements in psychological well-being, with mean GHQ-12 scores decreasing from 14.5 at baseline to 9 at follow-up ( P < .05). Dyspnea symptoms improved across both groups, with an average reduction of 3.5 points on the Modified Borg Scale. The SF-36 results indicated notable enhancements in both physical and mental health domains, showing mean improvements of 22% and 23%, respectively. No statistically significant difference was found between the 2 formulas, although FZYF showed slightly superior benefits in respiratory symptom relief. The retrospective analysis suggests that the FZYF may help alleviate long-term respiratory and psychological symptoms among COVID-19 convalescents, thereby potentially improving their overall quality of life. The FZAS, while showing comparable trends of benefit, appeared to exert relatively greater influence on mental and emotional well-being. However, these findings should be interpreted with caution given the non-randomized design and limited sample size, and further validation through large-scale controlled studies is warranted.
- 2 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (1) , e46375
Open AccessEffect of Fuzheng series of formulas on the psychological state, dyspnea, and quality of life in convalescent COVID-19 patients: A retrospective observational study
Post-infectious symptoms of COVID-19—such as persistent dyspnea, psychological disturbances, and reduced quality of life—continue to pose significant health challenges for convalescent patients. Traditional Chinese Medicine (TCM) has been widely used as a complementary therapeutic approach to alleviate post-COVID sequelae. This retrospective study evaluated the clinical effects of 2 TCM prescriptions, Fuzheng Yifei Formula (FZYF) and Fuzheng Anshen Formula (FZAS), on the psychological state, dyspnea, and quality of life among patients recovering from COVID-19. Medical records of 114 COVID-19 convalescent patients treated at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine were retrospectively reviewed. Based on the treatment regimen, patients were categorized into 2 groups: FZYF (n = 77) and FZAS (n = 37). Clinical data were collected at baseline, 7 days, 14 days, and during follow-up. Changes in psychological status, dyspnea severity, and quality-of-life scores were analyzed using validated assessment tools, including the General Health Questionnaire (GHQ-12), the Modified Borg Scale, and the 36-Item Short Form Survey (SF-36) Health Survey. Both FZYF and FZAS were associated with significant improvements in psychological well-being, with mean GHQ-12 scores decreasing from 14.5 at baseline to 9 at follow-up ( P < .05). Dyspnea symptoms improved across both groups, with an average reduction of 3.5 points on the Modified Borg Scale. The SF-36 results indicated notable enhancements in both physical and mental health domains, showing mean improvements of 22% and 23%, respectively. No statistically significant difference was found between the 2 formulas, although FZYF showed slightly superior benefits in respiratory symptom relief. The retrospective analysis suggests that the FZYF may help alleviate long-term respiratory and psychological symptoms among COVID-19 convalescents, thereby potentially improving their overall quality of life. The FZAS, while showing comparable trends of benefit, appeared to exert relatively greater influence on mental and emotional well-being. However, these findings should be interpreted with caution given the non-randomized design and limited sample size, and further validation through large-scale controlled studies is warranted.
- Open Access
Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study
Background: Real-world evidence on the effectiveness of inactivated vaccines against the Delta and Omicron (BA.2.38) variants remains scarce. Methods: A retrospective cohort study was conducted to estimate the adjusted vaccine effectiveness (aVE) of one, two, and three doses of inactivated vaccines in attenuating pneumonia, severe COVID-19, and the duration of viral shedding in Delta and Omicron cases using modified Poisson and linear regression as appropriate. Results: A total of 561 COVID-19 cases were included (59.2% Delta and 40.8% Omicron). In total, 56.4% (184) of Delta and 12.0% (27) of Omicron cases had COVID-19 pneumonia. In the two-dose vaccinated population, 1.4% of Delta and 89.1% of Omicron cases were vaccinated for more than 6 months. In Delta cases, the two-dose aVE was 52% (95% confidence interval, 39–63%) against pneumonia and 61% (15%, 82%) against severe disease. Two-dose vaccination reduced the duration of viral shedding in Delta cases, but not in booster-vaccinated Omicron cases. In Omicron cases, three-dose aVE was 68% (18%, 88%) effective against pneumonia, while two-dose vaccination was insufficient for Omicron. E-values were calculated, and the E-values confirmed the robustness of our findings. Conclusions: In Delta cases, two-dose vaccination within 6 months reduced pneumonia, disease severity, and the duration of viral shedding. Booster vaccination provided a high level of protection against pneumonia with Omicron and should be prioritized.
Open AccessEffectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study
Background: Real-world evidence on the effectiveness of inactivated vaccines against the Delta and Omicron (BA.2.38) variants remains scarce. Methods: A retrospective cohort study was conducted to estimate the adjusted vaccine effectiveness (aVE) of one, two, and three doses of inactivated vaccines in attenuating pneumonia, severe COVID-19, and the duration of viral shedding in Delta and Omicron cases using modified Poisson and linear regression as appropriate. Results: A total of 561 COVID-19 cases were included (59.2% Delta and 40.8% Omicron). In total, 56.4% (184) of Delta and 12.0% (27) of Omicron cases had COVID-19 pneumonia. In the two-dose vaccinated population, 1.4% of Delta and 89.1% of Omicron cases were vaccinated for more than 6 months. In Delta cases, the two-dose aVE was 52% (95% confidence interval, 39–63%) against pneumonia and 61% (15%, 82%) against severe disease. Two-dose vaccination reduced the duration of viral shedding in Delta cases, but not in booster-vaccinated Omicron cases. In Omicron cases, three-dose aVE was 68% (18%, 88%) effective against pneumonia, while two-dose vaccination was insufficient for Omicron. E-values were calculated, and the E-values confirmed the robustness of our findings. Conclusions: In Delta cases, two-dose vaccination within 6 months reduced pneumonia, disease severity, and the duration of viral shedding. Booster vaccination provided a high level of protection against pneumonia with Omicron and should be prioritized.